AdvanCell Isotopes is involved in the production and supply of Alpha Emitting Isotopes for Targeted Alpha Therapy for cancer. Targeted Alpha Therapy is a revolutionary treatment that uses alpha-emitting isotopes attached to molecules that deliver cytotoxic radiation direct to tumours, i.e. radiotherapy at the molecular level. AdvanCell’s goal is a safe and effective treatment for patients with multiple forms of cancer, that will become a standard of care.
Location: Australia, New South Wales, Sydney
Member count: 11-50
Total raised: $12.54685M
Founded date: 2019
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 24.08.2022 | Series B | $12.54685M | - | finsmes.co... |
Mentions in press and media 2
| Date | Title | Description | Category | Author | Source |
| 25.08.2022 | Australia-... | Sydney, Australia-based radiop... | - | - | vcbay.news... |
| 24.08.2022 | AdvanCell ... | AdvanCell, a Sydney, Australia... | Australia | - | finsmes.co... |